A phase 2a trial randomized, double-blind, placebo-controlled, parallel group trial to
determine whether NMN administration improves DKD, as indicated by a significantly greater
reduction in UACR compared with placebo administration. Eligible participants will be
randomized to receive either 1000 mg NMN or placebo twice daily.